CIK 0001819133 · Non-accelerated filer<br>Smaller reporting company
Tango Therapeutics, Inc.
Sign in to watch- Ticker
- TNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (857) 320-4900
- Business address
- 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
- Former names
- BCTG Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,858,086
- in 6 filings, $1.9M under 10b5-1 plans
Net −$1,858,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-03 | Beckman Daniella Chief Financial Officer | Sale | −10,204 | $12.26 | $125K | 184,410 |
| 2026-02-03 | Beckman Daniella Chief Financial Officer | Sale | −113 | $12.90 | $1K | 184,297 |
| 2026-02-03 | Weber Barbara Director, Executive Chair | Sale | −30,186 | $12.26 | $370K | 1,629,587 |
| 2026-02-03 | Weber Barbara Director, Executive Chair | Sale | −333 | $12.90 | $4K | 1,629,254 |
| 2026-02-03 | Crystal Adam President, R&D | Sale | −18,251 | $12.26 | $224K | 187,419 |
| 2026-02-03 | Crystal Adam President, R&D | Sale | −201 | $12.90 | $3K | 187,218 |
| 2026-02-02 | Beckman Daniella Chief Financial Officer | Grant or award | +44,330 | 194,614 | ||
| 2026-02-02 | Beckman Daniella Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +265,980 | 265,980 | ||
| 2026-02-02 | Weber Barbara Director, Executive Chair | Grant or award | +37,522 | 1,659,773 | ||
| 2026-02-02 | Weber Barbara Director, Executive Chair | Grant or award · Stock Option (Right to Buy) | +222,132 | 222,132 | ||
| 2026-02-02 | Crystal Adam President, R&D | Grant or award | +47,460 | 205,670 | ||
| 2026-02-02 | Crystal Adam President, R&D | Grant or award · Stock Option (Right to Buy) | +284,760 | 284,760 | ||
| 2026-01-08 | Peters Malte President & CEO | Grant or award | +350,000 | 367,500 | ||
| 2026-01-08 | Peters Malte President & CEO | Grant or award · Stock Option (Right to Buy) | +1,650,000 | 1,650,000 | ||
| 2026-01-02 | Lee Sung Director | Grant or award | +10,000 | 10,000 | ||
| 2026-01-02 | Lee Sung Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-11-03 | Peters Malte Director | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2025-10-23 | Third Rock Ventures IV, L.P. 10% owner | Sale | −477,401 | $10.15 | $4.8M | 13,386,574 |
| 2025-09-25 | Third Rock Ventures IV, L.P. 10% owner | Sale | −500,000 | $8.02 | $4.0M | 13,863,975 |
| 2025-09-16 | Third Rock Ventures IV, L.P. 10% owner | Sale | −363,541 | $7.04 | $2.6M | 14,363,975 |
Page 4 of 11 · 211 trades